Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. (Q34590786)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

review article

1 reference

title

Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Ulrich Baumann

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

language of work or name

English

0 references

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1229-1236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

On the enzymic defects in hereditary tyrosinemia

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Effects of succinylacetone on methyl alpha-D-glucoside uptake by the rat renal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Hyperinsulinism in tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Cardiomyopathy in tyrosinaemia type I is common but usually benign.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Nontransplant treatment of tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Nitisinone in the treatment of hereditary tyrosinaemia type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Lectin-reactive alpha-fetoprotein in tyrosinaemia type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

NTBC treatment in tyrosinaemia type I: long-term outcome in French patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

NTBC as palliative treatment in chronic tyrosinaemia type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinemia, and the activity of enzymes involved in tyrosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Corneal opacities associated with NTBC treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

21 January 2018

NTBC and alkaptonuria

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Natural history of alkaptonuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

Use of nitisinone in patients with alkaptonuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1229

10.1517/14656566.9.7.1229

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18422479%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference